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Serotype G9 strains have been detected sporadically and in localized outbreaks in various African countries,
including South Africa, Botswana, Malawi, Kenya, Cameroon, Nigeria, Ghana, Guinea-Bissau, Libya, and
Mauritius. Serotype G9 strains were analyzed to investigate genogroup characteristics, including subgroup
specificity, electropherotype, and P and G genotypes. In addition, the antigenic composition of the South
African G9 strains was assessed. African G9 strains were associated with both DS-1–like characteristics and
Wa-like characteristics, indicating the predisposition of G9 strains to frequently reassort. Despite these reas-
sortment events, serotype G9 strains appear to maintain antigenic character in the outer capsid protein, as
evident with the reaction of the South African G9 strains with the G9-specific monoclonal antibody F45:1.
Phylogenetic analysis clustered African G9 strains geographically, regardless of genogroup characteristics, into
1 lineage (IIId). Two groups of G9 strains, originating in India and Japan, were identified in this lineage.
Continuous surveillance of circulating rotavirus strains in Africa is vital to prepare for future vaccine imple-
mentation on a continent that clearly needs such preventative medicines.
Diarrhea remains a major contributor to the high rates
of childhood mortality in Africa. It has been estimated
that 1 of 6 children born in sub-Saharan Africa will die
before 5 years of age and that one-fifth of these deaths
will be from diarrhea [1]. Rotavirus is the single most
important etiological agent of diarrhea, responsible for
20%–25% of all diarrheal cases [1, 2]. Improvements
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in sanitation and the availability of clean water have
not decreased the rate of rotavirus diarrhea in devel-
oped countries, illustrating the need to develop vaccines
as the first strategy of prevention [3]. The availability
of a rotavirus vaccine may provide a new tool to address
the problem of child survival in Africa [1].
The rotavirus genome consists of 11 segments of
double-stranded RNA (dsRNA) that are easily separated
by polyacrylamide gel electrophoresis. The relative mi-
gration of RNA segments are used to differentiate
strains into long, short, supershort, and abnormal RNA
profiles [4]. Surrounding the dsRNA are 3 protein lay-
ers: the core, inner capsid, and outer capsid. Epitopes
on the inner capsid protein (VP6) determine group and
subgroup specificity. Seven rotavirus groups (A–G) and
4 subgroups (SG; SGI, SGII, SGI+II, and SG non-I non-
II) in group A have been identified. The outer capsid
proteins, VP7 and VP4, are able to independently elicit
neutralizing antibody responses and are classified ac-
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cording to G types and P types, respectively. There are 15 G
types and 27 P types, of which 11 G and 11 P types have been
found in humans [5–7].
Comparative analysis of the VP7 amino acid sequences from
different human and animal serotypes identified regions that
were divergent among serotypes, termed VR1–VR9 [8]. In ad-
dition, 6 antigenic regions (A, B, C, and F, corresponding to
VR5, VR7, VR8, and VR9, respectively, and D and E) have also
been identified on the basis of nucleotide sequence analysis of
rotavirus variants resistant to neutralization by VP7-specific
monoclonal antibodies [9, 10].
The typing of circulating rotavirus strains before 1990 in-
cluded studies in Central African Republic [11], Gambia [12],
Kenya [13], Nigeria [14], and South Africa [15]. In these Af-
rican settings, serotypes G1, G2, G3, and G4 were predominant,
and 22% of the rotavirus-positive samples were untypeable.
Additional studies in Malawi [16], Kenya [17], Ghana [18],
and Guinea-Bissau [19, 20] similarly identified serotypes G1–
G4 as predominant. The improvement in molecular techniques,
allowing G typing of cocirculating rotavirus strains, resulted in
only 12% of the rotavirus-positive samples being untypeable.
At the World Health Organization–sponsored African Ro-
tavirus Network workshops held during 1998–2004, genotypes
were determined for rotavirus strains from Namibia, Botswana,
Zimbabwe, Zambia, Tanzania, Kenya, Sudan, Nigeria, Cam-
eroon, Ghana, Ivory Coast, Burkino Faso, Tunisia, and Mau-
ritius. Similar to previous studies, serotypes G1–G4 were pre-
dominant, although G9 strains were detected in Ghana, Nigeria,
Kenya [21], Botswana, and Cameroon. Further analysis of the
untypeable strains from the African Rotavirus Network coun-
tries may result in the detection of unusual strains with altered
primer binding sites or of rotavirus strains of animal origin.
Human G9 rotavirus strains were first detected in the United
States in 1983 [22] and have been sporadically detected in
samples from children with diarrhea in Japan [23, 24] and
Thailand [25]. In India, serotype G9 strains were predominant
during 1986–1988 and during 1992–1993 [26]. After 1995, G9
strains began to be detected more frequently and emerged as
the fifth most important human serotype, rivaling the previ-
ously more common G1, G2, G3, and G4 serotypes in some
settings [27]. Reports have also described G9 strains in North
America [28], Latin America [29, 30, 31], Central America [32],
China [33], and Africa [32]. In addition, serotype G9 strains
have been isolated from animals, including pigs [34] and lambs
[35].
Two rotavirus vaccines have been licensed and implemented
in the expanded program of immunization schedules in many
countries [36, 37]. The first, Rotarix (GlaxoSmithKline Bio-
logicals) is a monovalent human rotavirus [36] bearing the
most globally common human rotavirus serotype (G1P[8]).
The second, RotaTeq (Merck), is a pentavalent bovine-human
reassortant containing the surface proteins for serotypes G1,
G2, G3, G4, and P[8] and retaining a bovine (WC3) genome
backbone [37]. Although doubts originally surfaced with regard
to the ability of these vaccine candidates to protect against the
emerging G9 strains, subsequent trials have demonstrated that
both vaccines are efficacious against G9 strains. The protection
is probably attributable to the association of G9 strains with
the P[8] genotype, which is present in both vaccine compo-
sitions [36, 37]. This article describes the characterization and
molecular analysis of the genotype G9 strains from Africa and
includes specimens from South Africa, Botswana, Kenya,
Ghana, Cameroon, and Mauritius.
MATERIALS AND METHODS
Stool selection. South African rotavirus-positive stool samples
( ) were obtained from historical collections availablenp 567
at the Medical Research Council–Diarrhoeal Pathogens Re-
search Unit (DPRU). Since 1983, diarrheal stool specimens have
been collected from the Ga-Rankuwa Hospital in the North
West Province as part of ongoing surveillance. These specimens
have been analyzed in part and described elsewhere [15, 38–
40]. In addition, diarrheal stool specimens were collected from
pathology laboratories and hospitals in South Africa (A.D.S.,
unpublished data). Fecal suspensions and raw stool samples
from these collections were stored at 20C.
From March 1998 through April 1999, 60 rotavirus-positive
stool specimens were collected from children aged !5 years
from the Vhembe region of the Limpopo Province, South Africa
(N. Potgeiter, unpublished data). From July 1997 through Feb-
ruary 2000, 894 rotavirus-positive stool samples were collected
from 3 health centers in the Upper East region of Ghana [41].
From July 1999 through May 2000, 124 rotavirus-positive stool
samples were collected from children with diarrhea attending
outpatient clinics in the Southwest and Western Provinces of
Cameroon [42]. As part of an ongoing rotavirus surveillance
project in Kenya during 1998–2002, 650 rotavirus-positive stool
specimens were collected from clinics and hospitals in Nairobi
and neighboring areas of Nanyuki, Kitui, Narok, and Nakuru
(J. Nyangao, unpublished data) [43]. From February 1999
through April 2000, 248 stool specimens were collected from
young children in clinics and hospitals in Nairobi and the sur-
rounding area (J.M., unpublished data). During 1999, human
rotavirus-positive stool samples ( ) were collected fromnp 10
young children in Gaborone, Botswana (T.S., unpublished
data). During 2000, rotavirus-positive stool samples from Mau-
ritius ( ) were sent to the DPRU for further analysis (N.np 40
Pyndiah, unpublished data).
Rotavirus detection. Various enzyme-linked immunosor-
bent assay (ELISA)–based kits have been used at the DPRU to
determine the presence of rotavirus in stool samples from South
African children. These include the Rotazyme II (Abbott Lab-
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oratories) during 1982–1985, Rotavirus ELISA (Dakopatt) dur-
ing 1985, Rotavirus EIA (International Diagnostics Laborato-
ries) during 1986–1990, Rotascreen Latex Agglutination assay
(Mercia Diagnostics) during 1988, Rotadan (Novamed) during
1991–1996, and IDEIA Rotavirus kit (Oxoid) since 1997. A
10% suspension of fecal material was made in distilled water
and kept at 4C until analysis. A 10% suspension of fecal ma-
terial was made in distilled water, and stool samples from
Ghana, Cameroon, and Kenya were screened using the IDEIA
Rotavirus kit, according to the manufacturer’s instructions.
Specimens collected in Mauritius were screened using electron
microscopy and polyacrylamide gel electrophoresis. Specimens
collected in Botswana were screened using Rotavirus ELISA Kit
(Trinity Biotech), and the results were confirmed using electron
microscopy.
VP7 and VP4 genotyping of rotavirus strains. The rota-
virus dsRNA was extracted and purified using the RNaid kit
(BIO 101), according to the manufacturer’s instructions. The
samples were characterized according to VP7 and VP4 types
with use of nested reverse-transcription polymerase chain re-
action (RT-PCR) methods and primers described elsewhere [16,
26, 44, 45].
Subgroup (VP6) ELISA. The subgroup specificity of the
serotype G9 strains was determined using an in-house mono-
clonal antibody ELISA, as described elsewhere [39]. The group-
specific [46] and subgroup-specific monoclonal antibodies [47]
were a kind donation from H. B. Greenberg (Stanford Uni-
versity, Stanford, CA).
Polyacrylamide gel electrophoresis. Rotavirus dsRNA was
extracted and run as described elsewhere [38]. The gels were
stained using the silver staining technique of Herring et al [48].
Cloning and sequencing of the VP7 and VP4 genes of se-
rotype G9 rotavirus strains. First-round VP7 RT-PCR prod-
ucts of selected South African, Cameroonian, Ghanaian, and
Mauritian G9 rotavirus strains were cloned into pGEM-T Easy
Vector (Promega), according to the manufacturer’s instruc-
tions. Plasmids were sequenced automatically using M13 for-
ward and reverse primers by DNA Sequencing Laboratory, Uni-
versity of Cape Town, and Core DNA Sequencing Laboratory,
University of Stellenbosch. First-round VP4 RT-PCR products
of 4 South African G9 rotavirus strains (5001DB/97, 8253NN/
98, 6818NN/99, and 6342LP/99) were also cloned and
sequenced.
First-round VP7 RT-PCR products from selected G9 strains
from Botswana and Kenya were cleaned using the QIAquick
PCR Purification Kit (Qiagen) and were sequenced by Gene
Care Molecular Genetics using forward and reverse primers
(sBeg and End9), according to Gouvea et al [45]. Only partial
sequences, lacking the 3′ and 5′ terminal ends of the VP7 genes,
were obtained and submitted to GenBank. A phylogenetic tree
was constructed using the TreeView Program [49], with genetic
distances generated on DNAMan computer software.
Nucleotide sequence accession numbers. The DNA se-
quences for the VP7 genes of the African G9 strains were sub-
mitted directly to GenBank and were assigned the following
accession numbers: 5001DB/97, AF529864; 4330LC/98,
AF529865; 6601LC/98, AF529866; 6610LC/98, AF529867;
8197LC/98, AF529868; 8253NN/98, AF529869; 6818NN/99,
AF529870; 6222LP/99, AF529871 and 6342LP/99, AF529872;
3710CM/99, AY816184; 3139CM/99, AY816183; GH1319/99,
AY211065; GH1416/99, AY211066; GH3550, AY21167;
GH3574/99, AY211068; MR4703/00, AY262746; MR4710/00,
AY262747; MR4723/00, AY262748, MR4730, AY262749; BS473/
99, DQ822597; KY1601/99, DQ822600; KY3147/99,
DQ822601; KY3162, DQ822602; BS1405/02, DQ822598;
BS1414/02, DQ822599; KY6894/02, DQ822603; and KY6923/
02, DQ822604. The DNA sequences for the VP8* genes of the
South African G9 strains were submitted directly to GenBank
and were assigned the following accession numbers: 5001DB/
97, AF529873; 8253NN/98, AF529875; 6818NN/99, AF529876;
and 6342LP/99, AF529874.
G (VP7) serotyping ELISA. VP7 serotyping was completed
according to the method previously described by Taniguchi et
al [50]. The following capture monoclonal antibodies were
used: G1 [KU4], G2 [S2–2G10], G3 [YO-IE2], G4 [ST-2G7]
[50] and G1 [5E8], G2 [IC10], G3 [159] [51], and G9 [F45:1]
[52]. Mab60 [51] was included as a control to detect the pres-
ence of the intact double-shelled viral particles. Each plate con-
tained negative controls, and the reactions were read spectro-
photometrically at 450 nm.
RESULTS
Serotype G9 strains have been detected in various African coun-
tries, including South Africa, Botswana, Malawi, Kenya, Cam-
eroon, Ghana, Libya, and Mauritius. The serotype G9 strains
were sporadically isolated in South Africa, Botswana, Kenya,
and Cameroon and appeared to be circulating at low levels in
the population. Serotype G9 strains were, however, the pre-
dominant serotype in some settings, including the Upper East
region of Ghana during 1999 and Mauritius during 2000.
South Africa genotype G9 strains. In South Africa, 7
G9P[6] strains with SGI specificity were isolated in the Gauteng
and Limpopo Provinces during 1997–1999 (SA5001DB/97,
SA4330LC/98, SA6601LC/98, SA6610LC/98, SA8197LC/98,
SA6222LP/99, and SA6342LP/99) (Figure 1). In addition, se-
rotype G9P[6] strains were predominant in the neonatal ward
of the Dr George Mukhari Hospital, Pretoria, and 2 isolates
were randomly selected for further analysis (SA8253NN/98 and
SA6818NN/99). These strains were first detected in the latter
part of 1998 and persisted in the ward during 1999, despite
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the introduction of G1P[8] and G1P[6] strains in the ward
during the rotavirus season in early 1999 [53].
The South African G9 strains were screened with the G9-
specific monoclonal antibody F45:1, and 7 of the 9 selected G9
strains (SA5001DB/97, SA4330LC/98, SA6601LC/98,
SA6610LC/98, SA8197LC/98, SA6818NN/99, and SA6222LP/
99) could be detected using this monoclonal antibody. The
failure of 2 samples (SA8253NN/98 and SA6342LP/99) to react
with any of the monoclonal antibodies was more likely attrib-
utable to low viral titers, because these samples also failed to
react with the group-specific Mab60.
Four of the South Africa G9 strains (5001DB/97, 8253NN/
98, 6818NN/99, and 6342LP/99) were selected for cloning and
sequencing of the VP8* subunit of the VP4 genes. The partial
VP4 sequences obtained were submitted to GenBank for a
BLASTn search on the National Centre for Biological Infor-
mation Web site (http://blast.ncbi.nlm.gov/Blast.cgi. All VP4
sequences from the strains isolated were most homologous to
the G9P[6] strain US1205 (AF079356), and the percentage of
nucleotide homology ranged from 99.1% to 99.8% (data not
shown).
African genotype G9 strains. From 1998 through 2001, 73
G9 strains were detected in Ghana, with the bulk of the SGII,
long electropherotype G9P[8] strains ( ) being isolatednp 49
in the Navrongo district during 1999 [41]. Four G9 strains,
representing 3 RNA electrophoretic patterns, were selected for
sequencing (GH1319/99, GH1416/99, GH3550/99, and
GH3745/99) (Figure 1).
In Cameroon, 8 G9 strains (2 with SGI, P[4] or P[6] ge-
notype, short RNA profiles and 6 with SGII, P[8], long RNA
profiles) were detected. Three isolates bearing the respective
genogroup characteristics were selected for sequencing
(3139CM/99, 3298CM/99, and 3710/99) (Figure 1). The pre-
dominant strain in both provinces during that time was G1P[8]
[42].
Serotype G9 strains were first detected in Nairobi, Kenya,
during 1999. The first strain, KY3147/99, displayed a long elec-
tropherotype, SGII specificity, and P[6], and the second,
KY3162/99, displayed a short electropherotype, SGI specificity,
and P[6] (Figure 1). Another G9 strain (KY1601/99), with a
long RNA profile, SGII specificity, and P[8] genotype (Figure
1), was collected in November 1999 from a child of unknown
age in Kibera, the largest African slum located southwest of
Nairobi city center (J.M., unpublished data).
The collection of stool specimens continued in Nairobi dur-
ing 2002, and an additional 8 G9 strains were detected (J.N.,
unpublished data). Five strains possessed a long electropher-
otype, SGII specificity, and P[8]; 2 had long electropherotype,
SGII specificity, and P[6], and a single strain showed a short
electropherotype, SGI, and P[4] (data not shown). Two strains,
KY6894/02 and KY6923, were selected for further analysis (Fig-
ure 1).
Despite the limited number of stool samples collected in
Botswana in 1999, a single SGI G9P[6] strain was identified
among the predominant G1 strains circulating (BS473/99) (Fig-
ure 1). Three years later, 4 SGI G9 strains were detected in
stool samples from Botswana (G.B., unpublished data). Two of
these strains (BS1405/02 and BS1414/02) were randomly se-
lected for further analysis (Figure 1).
During 2001, rotavirus-positive stool samples were sent to
the DPRU for further analysis (N. Pyndiah, unpublished data).
The majority of the samples ( ) collected in 2000 werenp 40
SGII, long electropherotype, G9P[8] strains ( ). Strainsnp 22
MR4703/00, MR4710/00, MR4723/00, and MR4730/00 were
randomly selected for sequencing (Figure 1).
Analysis of VP7 antigenic regions and phylogeny. The
amino acid sequences of antigenic regions A (amino acids 87–
101), B (amino acids 142–152), C (amino acids 208–221), and
F (amino acids 235–245) of African G9 strains and selected
international G9 strains were aligned and compared. Analysis
of the African G9 strains revealed point mutations at amino
acid positions 87, 208, 220, and 242 (Figure 1). Additional point
mutations in antigenic regions A and B were detected in strains
from South Africa (SA6222LP/99), Kenya (KY3147/99 and
KY3162/99), and Botswana (BS1405/02 and BS1414/02). In an-
tigenic region C, point mutations were noted in SA6610LC/98,
SA6342LP/99, and MR4710/00, and samples with SA6601LC/
98, SA8197LC/98, CM3139/99, CM3298/99, GH1416/99, and
KY6923/02 displayed point mutations in antigenic region D.
Phylogenetic analysis including African G9 strains and in-
ternational strains from various countries was performed to
determine the relationship between African G9 strains and
those isolated on other continents (Figure 2). All the African
G9 strains clustered in lineage IIId and tended to cluster geo-
graphically and not on the basis of genogroup characteristics.
DISCUSSION
The emergence of serotype G9 strains has prompted researchers
in various countries to include reagents capable of detecting
this once rare serotype. Serotype G9 strains (MW69) were first
identified in Africa in Malawi from July 1997 through January
1998 [16]. Part of this study attempted to identify serotype G9
strains in South Africa over the past 2 decades, and improved
typing protocols have allowed additional analysis to be per-
formed on historical stool collections. In South Africa, the first
G9 strain was isolated from a sample collected in October 1997.
BLASTn analysis revealed the highest homology to the VP7
genes of MW69. The VP4 genes of South African G9 strains
were shown to have the highest homology with US1205
(G9P[6]), isolated in the United States during 1996–1997.
A limitation of the South African study was that the selection
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Figure 2. Phylogenetic analysis of the full and partial VP7 nucleotide sequences of African and selected international G9 strains. The length of the
abscissa to the connecting node is proportional to the genetic distance between sequences and is indicated by the scale bar. Bootstrap values 190%
are indicated at the appropriate nodes. Lineages, as defined by Phan et al [61], are indicated where applicable. *Strains sequenced in this study.
criteria of the stool samples allowed for the identification of
only serotype G9 strains with short electropherotypes and SGI
specificity. Circulation of G9 strains with long electropherotypes
and SGII specificity in South Africa before 1997, therefore,
cannot be discounted. In fact, all serotype G9 strains isolated
globally during 1983, 1986, 1987, 1994, and 1995 (Figure 1)
displayed SGII specificity and long electropherotypes. The SGI,
P[6], short electropherotype G9 strains seem to have appeared
after 1995, and detection of these strains in southern Africa
since 1997 supports this idea.
Serotype G9 rotavirus strains were first isolated from an 18-
month-old child with gastroenteritis in Philadelphia, Pennsyl-
vania, in February 1983 [22]. The genogroup characteristics
associated with this strain included SGII specificity and a long
electropherotype. Subsequently, SGII, long RNA profile G9
strains were isolated in Japan in 1986 and 1987 [24, 54] and
in India in 1987 and 1994 [27, 55]. In 1995, a new generation
of serotype G9 strains appeared to emerge from various centers,
including Bangladesh [56]; Philadelphia, Pennsylvania [57];
and Japan (58, 59) (Figure 1). The reemerging G9 strain from
Japan (95H115/95) displayed the characteristic SGII, long elec-
tropherotype but grouped phylogenetically with G9 strains iso-
lated in the United States during 1995–1998 that displayed a
SGI short electropherotype. Recent studies on serotype G9
strains have shown that these strains are promiscuous, reas-
sorting with SGI, short electropherotype, or SGII long electro-
pherotype strains, while still maintaining an overall VP7 amino
acid identity of 190% [58, 60].
The serotype G9 strains detected in Africa were associated
with both DS-1–like characteristics (SGI, P[6], and short RNA
profile), and Wa-like characteristics (SGII, P[8], and long RNA
profile) (Figure 1). The G9 strains isolated in southern Africa
tended to display the former genogroup characteristics, whereas
strains from Kenya and Mauritius tended to display the latter
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genogroup characteristics. Although a G9 strain detected in
Botswana in 1999 (BS473) was more closely related to southern
African strains, G9 strains isolated in 2002 (BS1405 and
BS1414) seemed to be more closely related to those G9 strains
with SGII and long electropherotypes found in East and West
Africa, despite having SGI specificity and short electrophero-
types. These results further support the ideas that (1) serotype
G9 strains are promiscuous in nature and reassort frequently
and (2) rotavirus strains emerge from a pool of related strains
rather than evolve from previous epidemics.
In West Africa, G9 strains displaying either DS-1– or Wa-
like characteristics were also identified. Of interest, although
the genogroup characteristics did not differentiate strains from
Ghana or Kenya, a different picture emerged in Cameroon.
Four SGII, long electropherotype G9P[8] strains were collected
in the coastal South Western Province, and a single SGI, short
electropherotype G9P[4] strain was collected in the drier,
mountainous Western Province [42]. These strains also dem-
onstrated different phylogeny, with the SGII, long electropher-
otype strains clustering with East and West African strains and
the SGI, short electropherotype strain clustered with southern
African strains.
Analyses of antigenic regions A, B, C, and F revealed point
mutation at positions 87 (ArT), 208 (TrI), 220 (ArT), and
242 (TrN) in all African G9 strains (Figure 1). These point
mutations were consistent in almost all G9 strains detected after
1994 and seemed to originate from G9 strains detected in India
and Japan in 1994 and 1995, respectively. Phylogenetic analyses
also clustered all the African G9 strains with international G9
strains isolated after 1994 and in lineage IIId, as defined by
Phan et al [61]. In fact, African G9 strains appear to have
originated from 2 sources: India in 1994 and Japan in 1995
(Figure 2).
The reaction of 7 South African G9 strains with F45:1 shows
that despite the monoclonal antibody being developed against
an older G9 strain and amino acid substitutions occurring in
the antigenic regions, the antigenic character of the South Af-
rican strains has not altered sufficiently to allow escape. These
results support those of Hoshino et al [62] that the older lin-
eage-1 strains induce broad, cross-reactive, G9-specific anti-
bodies. In addition, F45:1 might prove to be useful in large-
scale epidemiological studies in Africa, especially in regions
where the cost of reagents and lack of equipment availability
prevent the use of molecular techniques for typing.
Despite the maintenance of overall amino acid homology,
subtle differences exist in the antigenic composition of the VP7
protein, and the nature and spectrum of anti-VP7 neutralizing
antibodies generated by different G9 strains has also been
shown to vary [62]. The global emergence of serotype G9 strains
has prompted fears that the current vaccine candidates may
not protect against these new serotypes. In fact, symptomatic
reinfection of vaccinated children with G9 has been shown to
be possible [37, 63], and as suggested by Phan et al [61], further
classification of G9 strains into lineages and sublineages may
aid in the identification of monotypes that escape vaccine-
generated immunity.
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